Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive source : Ir.anaptysbio.com save search
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
Published: 2022-10-05 (Crawled : 13:00) - ir.anaptysbio.com
ANAB | $21.45 0.85% 88K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: -0.76%
lung trials positive cancer
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
Published: 2021-11-15 (Crawled : 14:00) - ir.anaptysbio.com
ANAB | $21.45 0.85% 88K
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
phase 1 positive topline phase 2 phase 3
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
Published: 2020-10-13 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $21.45 0.85% 88K
|
Health Technology
|
| O: 1.01%
H: 5.5%
C: 4.96%
phase 2 positive trial topline psoriasis
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium -- Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
Published: 2021-01-16 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $21.45 0.85% 88K
|
Health Technology
| Email alert
Add to watchlist
test positive cancer gastrointestinal symposium dostarlimab
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
WISA 4 | $5.33 204.57% 190M
|
Electronic Technology
TPET | $0.5189 124.54% 38M
|
n/a
SXTC | $1.78 52.14% 33M
|
Health Technology
JAGX | $0.1771 49.07% 540M
|
Health Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
FNCH | $2.98 32.74% 400K
|
Professional, Scientific, and T...
PALI | $5.51 32.45% 28M
|
Manufacturing
VERO | $0.804 31.8% 110K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.